Table 3.
Factors Associated with Stable or Increased Fibrosis Stage by Univariate and Multivariable Logistic Regression
| Stable/Increased Fibrosis Stage (N=43) | Decreased Fibrosis Stage (N=29) | Univariate Analysis | Multivariable Analysisa | ||||
|---|---|---|---|---|---|---|---|
| Characteristic | Data Totalb | N (%) or median (IQR) | ORc (95% CI) | p-value | aORc (95% CI) | p-value | |
| Age, years | 72 | 32 (28–38) | 35 (29–42) | 0.98 (0.94–1.03) | 0.447 | ||
| Female | 72 | 24 (55.8%) | 20 (69%) | 0.57 (0.21–1.53) | 0.247 | ||
| BMI, kg/m2 | 72 | 24.7 (23–28.8) | 21.9 (19.5–24.4) | 1.23 (1.08–1.41) | 0.003 | 1.35 (1.13–1.62) | 0.001 |
| EtOH Use, yes | 72 | 11 (25.6%) | 8 (27.6%) | 0.90 (0.31–2.61) | 0.850 | ||
| Baseline log10 HBV DNA, IU/ml | 72 | 1.5 (0–2.3) | 3 (0–5.5) | 0.85 (0.72–1.01) | 0.053 | – | – |
| Baseline HBeAg Reactived | 70 | 8 (18.6%) | 6 (22.2%) | 0.71 (0.24–2.63) | 0.713 | ||
| Baseline log10 HIV RNA, copies/ml | 72 | 4.8 (4.2–5.4) | 4.3 (4.1–4.8) | 1.87 (0.99–3.58) | 0.058 | – | – |
| Baseline CD4+T-cells <200 cells/mm3 | 72 | 16 (37.2%) | 3 (10.3%) | 5.14 (1.34–19.7) | 0.017 | 0.99 (0.98–0.99) | 0.003 |
| BCP A1762T/G1764A | 28 | 6 (37.5%) | 8 (66.7%) | 0.30 (0.07–1.44) | 0.133 | – | – |
| PreS2 Indels | 14 | 1 (20%) | 4 (44.4%) | 0.31 (0.02–4.02) | 0.372 | ||
| Any Liver Disease Severity Mutatione | 29 | 9 (56.3%) | 11 (84.6%) | 0.23 (0.04–1.42) | 0.114 | – | – |
| Time on Antiretroviral Therapy, monthsf | 72 | 28 (18–31) | 27 (23–31) | 1.00 (0.99–1.01) | 0.543 | ||
| Follow-up HBV DNA <20 IU/mL at 36 months | 72 | 30 (69.8%) | 20 (69%) | 1.04 (0.37–2.88) | 0.942 | ||
| Follow-up HIV RNA <200 copies/mL at 36 months | 72 | 27 (62.8%) | 24 (82.8%) | 0.43 (0.16–1.15) | 0.094 | 0.20 (0.06–0.71) | 0.013 |
Abbreviations: BMI, body-mass-index; HBV, hepatitis B virus; HIV, human immunodeficiency virus; BCP, basal core promoter
Multivariable model controlled for baseline liver stiffness. Further covariates with p-value <0.20 in UV analysis were run in MV model via backward stepwise regression. – in MV column indicates covariates that were assessed and removed from final model due to non-significance.
Total number of patients with valid data for each variable. Values < 95 are representative of missing data, or insufficient sample / inability to sequence the patient sample
For all continuous variables, ORs are measured per unit increment;
Includes 5 patients with concurrent HBeAg and anti-HBe
Includes: BCP A1762T/G1764A mutation, 1766, 1753, F22S and preS2 deletion mutations
Time between ART initiation and follow-up TE scan